发布求助
文献互助 智能选刊 最新文献

Cancer Investigation最新文献

筛选
英文 中文
Immunohistochemical Analysis of Lung Adenocarcinoma in Russian Mayak Nuclear Workers. 俄罗斯Mayak核工人肺腺癌的免疫组化分析。
IF 2.4 4区 医学
Cancer Investigation Pub Date : 2023-09-01 DOI: 10.1080/07357907.2023.2218489
Gleb V Sychugov, Tamara V Azizova, Galina V Zhuntova, Evgeniya S Grigoryeva, Christopher A Loffredo, Nobuyuki Hamada, Evgeniy L Kazachkov
{"title":"Immunohistochemical Analysis of Lung Adenocarcinoma in Russian Mayak Nuclear Workers.","authors":"Gleb V Sychugov,&nbsp;Tamara V Azizova,&nbsp;Galina V Zhuntova,&nbsp;Evgeniya S Grigoryeva,&nbsp;Christopher A Loffredo,&nbsp;Nobuyuki Hamada,&nbsp;Evgeniy L Kazachkov","doi":"10.1080/07357907.2023.2218489","DOIUrl":"https://doi.org/10.1080/07357907.2023.2218489","url":null,"abstract":"<p><p>Specimens of lung adenocarcinoma (AdCa) from Russian nuclear workers (<i>n</i> = 54) exposed to alpha particles and gamma rays and from individuals non-exposed to radiation (<i>n</i> = 21) were examined using immunohistochemistry. Estimated significant associations with alpha dose were negative for Ki-67 and collagen IV in AdCa. Associations with gamma-ray dose were negative for tissue inhibitor of matrix metalloproteinase 2 and caspase 3 and positive for matrix metalloproteinase 2 and leukemia inhibiting factor in AdCa. The findings provide some evidence supporting alterations in apoptosis, cell proliferation and extracellular matrix in lung tissues affected by chronic radiation exposure that can contribute to radiogenic cancerogenesis.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":"41 7","pages":"686-698"},"PeriodicalIF":2.4,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10166550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Drug Repurposing Analysis for Colorectal Cancer through Network Medicine Framework: Novel Candidate Drugs and Small Molecules. 通过网络医学框架对癌症大肠癌的药物再利用分析：新的候选药物和小分子。
IF 2.4 4区 医学
Cancer Investigation Pub Date : 2023-09-01 Epub Date: 2023-09-08 DOI: 10.1080/07357907.2023.2255672
Ulku Unal, Esra Gov
{"title":"Drug Repurposing Analysis for Colorectal Cancer through Network Medicine Framework: Novel Candidate Drugs and Small Molecules.","authors":"Ulku Unal,&nbsp;Esra Gov","doi":"10.1080/07357907.2023.2255672","DOIUrl":"10.1080/07357907.2023.2255672","url":null,"abstract":"<p><p>This study aimed to reveal the drug-repurposing candidates for colorectal cancer (CRC) <i>via</i> drug-repurposing methods and network biology approaches. A novel, differentially co-expressed, highly interconnected, and co-regulated prognostic gene module was identified for CRC. Based on the gene module, polyethylene glycol (PEG), gallic acid, pyrazole, cordycepin, phenothiazine, pantoprazole, cysteamine, indisulam, valinomycin, trametinib, BRD-K81473043, AZD8055, dovitinib, BRD-A17065207, and tyrphostin AG1478 presented as drugs and small molecule candidates previously studied in the CRC. Lornoxicam, suxamethonium, oprelvekin, sirukumab, levetiracetam, sulpiride, NVP-TAE684, AS605240, 480743.cdx, HDAC6 inhibitor ISOX, BRD-K03829970, and L-6307 are proposed as novel drugs and small molecule candidates for CRC.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"713-733"},"PeriodicalIF":2.4,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10173920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intraosseous Spindle Cell Rhabdomyosarcoma with MEIS1::NCOA2 Fusion - Case Report with Substantial Clinical Follow-up and Review of the Literature. 伴有MEIS1:：NCOA2融合的骨内梭形细胞横纹肌肉瘤——病例报告及大量临床随访和文献复习。
IF 2.4 4区 医学
Cancer Investigation Pub Date : 2023-09-01 Epub Date: 2023-09-06 DOI: 10.1080/07357907.2023.2255668
Benjamin F Smith, Yee-Cheen Doung, Brooke Beckett, Christopher L Corless, Lara E Davis, Jessica L Davis
{"title":"Intraosseous Spindle Cell Rhabdomyosarcoma with <i>MEIS1</i>::<i>NCOA2</i> Fusion - Case Report with Substantial Clinical Follow-up and Review of the Literature.","authors":"Benjamin F Smith,&nbsp;Yee-Cheen Doung,&nbsp;Brooke Beckett,&nbsp;Christopher L Corless,&nbsp;Lara E Davis,&nbsp;Jessica L Davis","doi":"10.1080/07357907.2023.2255668","DOIUrl":"10.1080/07357907.2023.2255668","url":null,"abstract":"<p><p>Spindle cell/sclerosing rhabdomyosarcoma (SSRMS) is a clinicopathologically and molecularly heterogeneous disease. Gene fusions have been identified in intraosseous SSRMS, consisting predominantly of <i>EWSR1</i>/<i>FUS</i>::<i>TFCP2</i> and <i>MEIS1</i>::<i>NCOA2</i>. The former often follow an aggressive clinical course; there is limited clinical follow-up available for the latter. We report here a new case of the very rare intraosseous SSRMS with <i>MEIS1</i>::<i>NCOA2</i> gene fusion and include the detailed treatment course and 52 months of clinical follow-up. SSRMS with <i>MEIS1</i>::<i>NCOA2</i> gene fusion appears biologically distinct from other intraosseous SSRMS, following a course characterized by local recurrence with rare reports of metastasis to date.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"704-712"},"PeriodicalIF":2.4,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10158690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and Safety of RET-Specific Kinase Inhibitors in RET-Altered Cancers: A Systematic Review. RET特异性激酶抑制剂在RET改变的癌症中的疗效和安全性：一项系统综述。
IF 2.4 4区 医学
Cancer Investigation Pub Date : 2023-09-01 Epub Date: 2023-10-31 DOI: 10.1080/07357907.2023.2255655
Muhammad Ashar Ali, Syed S Shah, Rimsha Ali, Shammas Farooq Bajwa, Sana Rehman, Aqsa Anwar, Muhammad Yasir Anwar, Memoona Saeed, Nayab Mirza, Wajeeha Aiman
{"title":"Efficacy and Safety of RET-Specific Kinase Inhibitors in RET-Altered Cancers: A Systematic Review.","authors":"Muhammad Ashar Ali,&nbsp;Syed S Shah,&nbsp;Rimsha Ali,&nbsp;Shammas Farooq Bajwa,&nbsp;Sana Rehman,&nbsp;Aqsa Anwar,&nbsp;Muhammad Yasir Anwar,&nbsp;Memoona Saeed,&nbsp;Nayab Mirza,&nbsp;Wajeeha Aiman","doi":"10.1080/07357907.2023.2255655","DOIUrl":"10.1080/07357907.2023.2255655","url":null,"abstract":"<p><p>RET proto-oncogene encodes receptor tyrosine kinase. Selpercatinib and pralsetinib are the only RET-specific tyrosine kinase inhibitors approved by FDA in RET-altered tumors. We searched PubMed, Embase, Cochrane, WOS, and Clinicaltrials.gov. Objective-response, complete-response, and partial-response were 60-89%, 0-11%, and 55-89%, respectively, with the use of RET-specific drugs. ≥Grade 3 adverse events were seen in 28-53% of the patients, with hypertension, change in ALT, QT prolongation, neutropenia, and pneumonitis among the common side effects. Hence, selpercatinib and pralsetinib were effective and well tolerated by most of the patients with RET-altered tumors.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"739-749"},"PeriodicalIF":2.4,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41107922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction. 校正
IF 2.4 4区 医学
Cancer Investigation Pub Date : 2023-09-01 Epub Date: 2023-10-31 DOI: 10.1080/07357907.2023.2259655
{"title":"Correction.","authors":"","doi":"10.1080/07357907.2023.2259655","DOIUrl":"10.1080/07357907.2023.2259655","url":null,"abstract":"","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"750"},"PeriodicalIF":2.4,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41124931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Impact of Cancer-Associated Fibroblasts on Drug Resistance, Stemness, and Epithelial-Mesenchymal Transition in Bladder Cancer: A Comparison between Recurrent and Non-Recurrent Patient-Derived CAFs. 癌症相关成纤维细胞对膀胱癌耐药、干细胞和上皮-间质转化的影响:复发性和非复发性患者源性CAFs的比较
IF 2.4 4区 医学
Cancer Investigation Pub Date : 2023-09-01 DOI: 10.1080/07357907.2023.2237576
Nima Rastegar-Pouyani, Vahideh Montazeri, Nikoo Marandi, Shima Aliebrahimi, Melika Andalib, Emad Jafarzadeh, Hamed Montazeri, Seyed Nasser Ostad
{"title":"The Impact of Cancer-Associated Fibroblasts on Drug Resistance, Stemness, and Epithelial-Mesenchymal Transition in Bladder Cancer: A Comparison between Recurrent and Non-Recurrent Patient-Derived CAFs.","authors":"Nima Rastegar-Pouyani,&nbsp;Vahideh Montazeri,&nbsp;Nikoo Marandi,&nbsp;Shima Aliebrahimi,&nbsp;Melika Andalib,&nbsp;Emad Jafarzadeh,&nbsp;Hamed Montazeri,&nbsp;Seyed Nasser Ostad","doi":"10.1080/07357907.2023.2237576","DOIUrl":"https://doi.org/10.1080/07357907.2023.2237576","url":null,"abstract":"<p><p>This study comparatively evaluated the possible effects of recurrent and non-recurrent patient-derived Cancer-Associated Fibroblasts (CAFs-R and -NR) on the bladder cancer cell line, EJ138. Both groups of CAFs increased cisplatin resistance and altered cell cycle distribution alongside induced resistance to apoptosis. Later, the scratch assay confirmed the cell migration-inducing effects of CAFs on cells. Nonetheless, only CAFs-R managed to increase sphere-formation and clonogenic levels in EJ138 cells, which were later validated by upregulating pluripotency transcription factors. Besides, CAFs-R also affected the expression levels of some of the EMT markers. Our study suggests that CAFs-R had stronger pro-tumorigenic effects on EJ138 cells.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":"41 7","pages":"656-671"},"PeriodicalIF":2.4,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10157610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Platinum Sensitivity in IDH1/2 Mutated Intrahepatic Cholangiocarcinoma: Not All "BRCAness" Is Created Equal. IDH1/2突变肝内胆管癌的铂敏感性:并非所有的“BRCAness”都是平等的。
IF 2.4 4区 医学
Cancer Investigation Pub Date : 2023-09-01 DOI: 10.1080/07357907.2023.2242957
Deborah Blythe Doroshow, Wei Wei, Meenakshi Mehrotra, Daniella Sia, Joseph Paul Eder, Ranjit Bindra, Jane Houldsworth, Patricia LoRusso, Zenta Walther
{"title":"Platinum Sensitivity in <i>IDH1/2</i> Mutated Intrahepatic Cholangiocarcinoma: Not All \"BRCAness\" Is Created Equal.","authors":"Deborah Blythe Doroshow,&nbsp;Wei Wei,&nbsp;Meenakshi Mehrotra,&nbsp;Daniella Sia,&nbsp;Joseph Paul Eder,&nbsp;Ranjit Bindra,&nbsp;Jane Houldsworth,&nbsp;Patricia LoRusso,&nbsp;Zenta Walther","doi":"10.1080/07357907.2023.2242957","DOIUrl":"https://doi.org/10.1080/07357907.2023.2242957","url":null,"abstract":"<p><p>Preclinical data suggest that <i>IDH1/2</i> mutations result in defective homologous recombination repair (HRR). We hypothesized that patients with <i>IDH1/2</i>mt intrahepatic cholangiocarcinoma (IHCC) would benefit more from 1 L platinum chemotherapy than patients with wildtype (WT) tumors. We performed a multicenter retrospective study of 81 patients with unresectable IHCC treated with 1 L platinum with a primary endpoint of clinical benefit rate (CBR). Patients with <i>IDH1/2</i>mt tumors had a similar CBR and objective response rate compared to those with <i>IDH</i> WT disease (59 versus 54%; <i>p</i> = 0.803), suggesting that a relationship between platinum sensitivity and HRR gene defects may be specific to tumor context.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":"41 7","pages":"646-655"},"PeriodicalIF":2.4,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10164333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Perception, Cognition and Thought: Part II Symbolic Processing and Language. 知觉、认知与思维:第二部分:符号加工与语言。
IF 2.4 4区 医学
Cancer Investigation Pub Date : 2023-09-01 DOI: 10.1080/07357907.2023.2233317
Gary H Lyman
{"title":"Perception, Cognition and Thought: Part II Symbolic Processing and Language.","authors":"Gary H Lyman","doi":"10.1080/07357907.2023.2233317","DOIUrl":"https://doi.org/10.1080/07357907.2023.2233317","url":null,"abstract":"","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":"41 7","pages":"617-620"},"PeriodicalIF":2.4,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10168558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
A Nomogram for Predicting Survival in Advanced Non-Small-Cell Lung Carcinoma Patients: A Population-Based Study. 预测晚期非小细胞肺癌患者生存的Nomogram:一项基于人群的研究。
IF 2.4 4区 医学
Cancer Investigation Pub Date : 2023-09-01 DOI: 10.1080/07357907.2023.2241547
Bo Yang, Mengmeng Teng, Haisheng You, Yalin Dong, Siying Chen
{"title":"A Nomogram for Predicting Survival in Advanced Non-Small-Cell Lung Carcinoma Patients: A Population-Based Study.","authors":"Bo Yang,&nbsp;Mengmeng Teng,&nbsp;Haisheng You,&nbsp;Yalin Dong,&nbsp;Siying Chen","doi":"10.1080/07357907.2023.2241547","DOIUrl":"https://doi.org/10.1080/07357907.2023.2241547","url":null,"abstract":"<p><p>Non-small-cell lung cancer (NSCLC) remains the most common malignant cancer. We identified 43140 advanced NSCLC patients from the SEER database to develop and validate a new prognostic model. The prognostic performance was evaluated by <i>P</i> value, concordance index, net reclassification index, integrated discrimination improvement, and decision curve analysis. The following variables were contained in the final prognostic model: age, sex, race, TNM stage, and grade and treatment options. Compared to the AJCC staging system, this prognostic model is conducive to the implementation of individualized clinical treatment schemes and can be an important part of the precise medical care of NSCLC tumors.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":"41 7","pages":"672-685"},"PeriodicalIF":2.4,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10223098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Perception, Cognition and Thought: Part III: Reasoning, Judgement and Decision-Making. 感知、认知和思维：第三部分：推理、判断和决策。
IF 2.4 4区 医学
Cancer Investigation Pub Date : 2023-09-01 Epub Date: 2023-07-27 DOI: 10.1080/07357907.2023.2238944
Gary H Lyman, Nicole M Kuderer
{"title":"Perception, Cognition and Thought: Part III: Reasoning, Judgement and Decision-Making.","authors":"Gary H Lyman,&nbsp;Nicole M Kuderer","doi":"10.1080/07357907.2023.2238944","DOIUrl":"10.1080/07357907.2023.2238944","url":null,"abstract":"","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"699-703"},"PeriodicalIF":2.4,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10257805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
首页 上一页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信